Accolade, Inc. (NASDAQ:ACCD – Get Rating) CEO Rajeev Singh sold 1,456 shares of Accolade stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $11.82, for a total value of $17,209.92. Following the completion of the sale, the chief executive officer now owns 564,205 shares of the company’s stock, valued at $6,668,903.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Rajeev Singh also recently made the following trade(s):
- On Monday, May 22nd, Rajeev Singh sold 1,578 shares of Accolade stock. The shares were sold at an average price of $10.90, for a total value of $17,200.20.
- On Wednesday, May 17th, Rajeev Singh sold 230 shares of Accolade stock. The shares were sold at an average price of $10.47, for a total value of $2,408.10.
- On Tuesday, April 18th, Rajeev Singh sold 220 shares of Accolade stock. The shares were sold at an average price of $14.58, for a total value of $3,207.60.
Accolade Stock Performance
Shares of ACCD stock traded up $0.11 during trading hours on Friday, hitting $11.32. 37,787 shares of the company’s stock were exchanged, compared to its average volume of 682,787. The company has a current ratio of 3.06, a quick ratio of 3.06 and a debt-to-equity ratio of 0.60. Accolade, Inc. has a fifty-two week low of $5.24 and a fifty-two week high of $17.00. The firm has a 50 day moving average of $13.00 and a two-hundred day moving average of $10.96.
Hedge Funds Weigh In On Accolade
Several hedge funds have recently bought and sold shares of the company. Ameriprise Financial Inc. lifted its stake in Accolade by 111.2% during the 1st quarter. Ameriprise Financial Inc. now owns 252,483 shares of the company’s stock worth $3,631,000 after acquiring an additional 132,925 shares in the last quarter. Titleist Asset Management LLC acquired a new stake in Accolade in the 1st quarter valued at about $1,409,000. JPMorgan Chase & Co. raised its position in Accolade by 4.6% in the 1st quarter. JPMorgan Chase & Co. now owns 5,893,057 shares of the company’s stock valued at $84,743,000 after purchasing an additional 259,910 shares in the last quarter. Rockefeller Capital Management L.P. raised its position in Accolade by 9.0% in the 1st quarter. Rockefeller Capital Management L.P. now owns 12,100 shares of the company’s stock valued at $174,000 after purchasing an additional 1,000 shares in the last quarter. Finally, State Street Corp raised its position in Accolade by 2.8% in the 1st quarter. State Street Corp now owns 1,504,944 shares of the company’s stock valued at $21,641,000 after purchasing an additional 40,580 shares in the last quarter. Institutional investors and hedge funds own 79.01% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts have issued reports on ACCD shares. SpectralCast reiterated a “reiterates” rating on shares of Accolade in a research note on Friday, April 28th. Bank of America upgraded Accolade from a “neutral” rating to a “buy” rating and set a $16.50 target price on the stock in a research note on Wednesday. Wells Fargo & Company boosted their price target on Accolade from $10.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Friday, April 21st. Jefferies Financial Group lowered Accolade from a “buy” rating to a “hold” rating and set a $14.00 price target on the stock. in a research note on Thursday, February 9th. Finally, 1-800-FLOWERS.COM reaffirmed a “reiterates” rating on shares of Accolade in a report on Friday, April 28th. Five analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $14.74.
Accolade, Inc, together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists.
- Get a free copy of the StockNews.com research report on Accolade (ACCD)
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
Receive News & Ratings for Accolade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accolade and related companies with MarketBeat.com's FREE daily email newsletter.